Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors

Biomedicines, Journal Year: 2023, Volume and Issue: 11(10), P. 2761 - 2761

Published: Oct. 12, 2023

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation in the livers of patients without a history alcohol abuse. It classified as either simple steatosis (nonalcoholic liver) or nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and hepatocellular carcinoma (HCC). Recently, it was suggested that terms “metabolic dysfunction-associated steatotic (MASLD)” (MASH)” should replace “nonalcoholic (NAFLD)” (NASH)”, respectively, with small changes definitions. MASLD, hepatic manifestation metabolic syndrome, rapidly increasing incidence globally, becoming an increasingly important cause HCC. Steatohepatitic HCC, histological variant its morphological features resembling non-neoplastic closely associated underlying syndrome. Variations genes including patatin-like phospholipase domain-containing protein 3 (PNPLA3), transmembrane 6 superfamily 2 (TM6SF2), membrane-bound O-acyltransferase 7 (MBOAT7) are natural HCC development. The mechanisms development MASLD have not been fully elucidated; however, various factors, lipotoxicity, inflammation, reactive oxygen species, insulin resistance, alterations gut bacterial flora, pathogenesis MASLD-associated Obesity also recognized risk factors for adenomas, recent meta-analyses shown association between intrahepatic cholangiocarcinoma. In this review, we outline pathology tumors.

Language: Английский

Epidemiological characteristics and precise prophylaxis and control of HBV-associated primary liver cancer

Hepatoma Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Primary liver cancer (PLC), which includes hepatocellular carcinoma (HCC, 93% in China; 75%-80% worldwide), intrahepatic cholangiocarcinoma (ICC, 4.3% 10%-15% and combined (CHC, 1.6% China), is a global disease that brings heavy burden to the world number of incidence cases on rise. Chronic injury caused by factors such as exposure aflatoxin B1, infection with Clonorchis sinensis, alcohol consumption, chronic hepatitis C virus (HCV), metabolic syndrome are all known risk for PLC. Notably, B (HBV) major factor HCC. Globally, PLC changing from infectious causes factors. Here, we update mechanisms HBV-related HCC (HBV-HCC) development, especially effect HBV evolution development The mutations, viral load, integration, together parameters poor function, key components define highest-risk population HBV-HCC. Antiviral therapy has been proven be effective prevention HBV-HCC population. Non-invasive imaging markers economical convenient screening early Surgical resection transplantation therapeutic options HCC; however, postoperative recurrence reaches 70% five years. Targeted therapy, immunotherapy, radiotherapy can improve survival Active prophylaxes, including vaccination, antiviral treatment, improving lifestyle decrease inflammation, surveillance, cost-effective decreasing

Language: Английский